Business Wire

CA-NEXON-AMERICA

17.11.2022 23:32:40 CET | Business Wire | Press release

Share
Embark on the First of Two Fantasy Life Updates in Mabinogi’s Winter Season

Mabinogi, Nexon’s free-to-play fantasy MMORPG, begins the winter season with two meaningful events. Entitled “NEXT,” these two-part game updates include overhauled character growth, faster and more convenient leveling, plus revised tutorials and UI improvements during November, and the introduction of Arcana talents in December!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117006144/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mabinogi, Nexon America's fantasy life MMORPG (Graphic: Business Wire)

Blaanid, the eager Memory Spirit, has prepared a new tutorial for all Milletians, making leveling and questing in Mabinogi faster overall! And Memoir Quests have been changed to now reward you for completing Generation quests. In Mabinogi's Masterpiece Update, Original Generation 1-3 Questline has been revamped to provide a friendly experience for new players as well as the ability to replay the quests for existing players. Mabinogi players new and old will find the starting experience even more user friendly! These updates, along with other elements such as Dan Advancement test improvements, and balance changes to Renown, Grandmaster, and Crusader skills are designed to drastically improve the early to mid-game leveling experience for all Milletians.

Memoir Rewards

  • Comfortable Growth - The perfect path to growth is Blaanid’s Brave Boost, which will grant you:
    • Skills trained by Talent
    • Upgraded and Reforged Memorial weapons
    • Pet & Doll Bag Support
    • and more!
  • Essential Skills & Benefits - Blaanid prepared even more gifts for new Milletians!
    • Your stats are increased as each Memoir Book is completed.
      • Recall Book Stage 1~4
      • Movement Speed +2%~8%
      • All Stats +1~4
      • Additional +1~4 AP at Rebirth!

Memorial Link

  • You can obtain this skill by completing the 2nd Memoir Book in Blaanid’s Brave Boost quests!
    • Skill allows a soul connection with pets
    • Pets can be used to draw enemy aggro
    • As pets increase in level and skill, pets and player Defense and Protection stats increase proportionally

In addition to the above improvements, Quests have been reorganized, only displaying essential quests now, and skill training has also been improved - less training points are required and more EXP is earned to quickly achieve high ranked skills. Lastly, Mabinogi has removed CP Training, meaning monster levels are no longer relevant for your training requirements. Other changes, such as teleporting to Moon Gate and Mana Tunnels, were improved in this update to make it more convenient for new and returning players to traverse the world map.

In part two of the “NEXT” update coming in December, Mabinogi unveils a new pair of Hybrid Talents, merging two talent styles into a single devastating package! Get ready to experience the almighty power of the Elemental Knight or the soulful skill of the Harmonic Saint when the Arcana update arrives later in December!

These reasons, and many more, are why your “NEXT” MMORPG should be Mabinogi!

For more information on Mabinogi, visit the official website and follow @MabiOfficial on Twitter for the latest updates.

Assets: Image

Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord

About Mabinogi http://mabinogi.nexon.net/

Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.

About Nexon America Inc. https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006144/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye